Background: Despite advancements in percutaneous coronary intervention, a significant proportion of ST-elevation myocardial infarction (STEMI) survivors develop long-term adverse left ventricular ... Show moreBackground: Despite advancements in percutaneous coronary intervention, a significant proportion of ST-elevation myocardial infarction (STEMI) survivors develop long-term adverse left ventricular (LV) remodelling, which is associated with poor prognosis. Adverse remodelling is difficult to predict, however four-dimensional (4D) flow cardiovascular magnetic resonance (CMR) can measure various aspects of LV intra-cavity flow beyond LV ejection fraction and is well equipped for exploring the underlying mechanical processes driving remodelling. The aim for this study was to compare acute 4D flow CMR parameters between patients who develop adverse remodelling with patients who do not. Methods: Fifty prospective 'first-event' STEMI patients underwent CMR 5 days post-reperfusion, which included cine-imaging, and 4D flow for assessing in-plane kinetic energy (KE), residual volume, peak-E and peak-A wave KE (indexed for LV end-diastolic volume [LVEDV]). All subjects underwent follow-up cine CMR imaging at 12 months to identify adverse remodelling (defined as 20% increase in LVEDV from baseline). Quantitative variables were compared using unpaired student's t-test. Tests were deemed statistically significant when p < 0.05. Results: Patients who developed adverse LV remodelling by 12 months had significantly higher in-plane KE (54 +/- 12 vs 42 +/- 10%, p = 0.02), decreased proportion of direct flow (27 +/- 9% vs 11 +/- 4%, p < 0.01), increased proportion of delayed ejection flow (22 +/- 9% vs 12 +/- 2, p < 0.01) and increased proportion of residual volume after 2 consecutive cardiac cycles (64 +/- 14 vs 34 +/- 14%, p < 0.01), in their acute scan. Conclusion: Following STEMI, increased in-plane KE, reduced direct flow and increased residual volume in the acute scan were all associated with adverse LV remodelling at 12 months. Our results highlight the clinical utility of acute 4D flow in prognostic stratification in patients following myocardial infarction. Show less
Ben-Arzi, H.; A. das; Kelly, C.; Geest, R.J. van der; Plein, S.; Dall'Armellina, E. 2021
Background Four-dimensional (4D) flow cardiac magnetic resonance (cardiac MR) imaging provides quantification of intracavity left ventricular (LV) flow kinetic energy (KE) parameters in three... Show moreBackground Four-dimensional (4D) flow cardiac magnetic resonance (cardiac MR) imaging provides quantification of intracavity left ventricular (LV) flow kinetic energy (KE) parameters in three dimensions. ST-elevation myocardial infarction (STEMI) patients have been shown to have altered intracardiac blood flow compared to controls; however, how 4D flow parameters change over time has not been explored previously. Purpose Measure longitudinal changes in intraventricular flow post-STEMI and ascertain its predictive relevance of long-term cardiac remodeling. Study Type Prospective. Population Thirty-five STEMI patients (M:F = 26:9, aged 56 +/- 9 years). Field Strength/Sequence A 3 T/3D EPI-based, fast field echo (FFE) free-breathing 4D-flow sequence with retrospective cardiac gating. Assessment Serial imaging at 3-7 days (V1), 3-months (V2), and 12-months (V3) post-STEMI, including the following protocol: functional imaging for measuring volumes and 4D-flow for calculating parameters including systolic and peakE-wave LVKE, normalized to end-diastolic volume (iEDV) and stroke volume (iSV). Data were analyzed by H.B. (3 years experience). Patients were categorized into two groups: preserved ejection fraction (pEF, if EF > 50%) and reduced EF (rEF, if EF < 50%). Statistical Tests Independent sample t-tests were used to detect the statistical significance between any two cohorts. P < 0.05 was considered statistically significant. Results Across the cohort, systolic KEi(sv) was highest at V1 (28.0 +/- 4.4 mu J/mL). Patients with rEF retained significantly higher systolic KEi(sv) than patients with pEF at V2 (18.2 +/- 3.4 mu J/mL vs. 6.9 +/- 0.6 mu J/mL, P < 0.001) and V3 (21.6 +/- 5.1 mu J/mL vs. 7.4 +/- 0.9 mu J/mL, P < 0.001). Patients with pEF had significantly higher peakE-wave KEi(EDV) than rEF patients throughout the study (V1: 25.4 +/- 11.6 mu J/mL vs. 18.1 +/- 9.9 mu J/mL, P < 0.03, V2: 24.0 +/- 10.2 mu J/mL vs. 17.2 +/- 12.2 mu J/mL, P < 0.05, V3: 27.7 +/- 14.8 mu J/mL vs. 15.8 +/- 7.6 mu J/mL, P < 0.04). Data Conclusion Systolic KE increased acutely following MI; in patients with pEF, this decreased over 12 months, while patients with rEF, this remained raised. Compared to patients with pEF, persistently lower peakE-wave KE in rEF patients is suggestive of early and fixed impairment in diastolic function. Evidence Level 1 Technical Efficacy Stage 3 Show less
After a reperfused myocardial infarction (MI), dynamic tissue changes occur (edema, inflammation, microvascular obstruction, hemorrhage, cardiomyocyte necrosis, and ultimately replacement by... Show moreAfter a reperfused myocardial infarction (MI), dynamic tissue changes occur (edema, inflammation, microvascular obstruction, hemorrhage, cardiomyocyte necrosis, and ultimately replacement by fibrosis). The extension and magnitude of these changes contribute to long-term prognosis after MI. Cardiac magnetic resonance (CMR) is the gold-standard technique for noninvasive myocardial tissue characterization. CMR is also the preferred methodology for the identification of potential benefits associated with new cardioprotective strategies both in experimental and clinical trials. However, there is a wide heterogeneity in CMR methodologies used in experimental and clinical trials, including time of post-MI scan, acquisition protocols, and, more importantly, selection of endpoints. There is a need for standardization of these methodologies to improve the translation into a real clinical benefit. The main objective of this scientific expert panel consensus document is to provide recommendations for CMR endpoint selection in experimental and clinical trials based on pathophysiology and its association with hard outcomes. (C) 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. Show less
Garg, P.; Geest, R.J. van der; Swoboda, P.P.; Crandon, S.; Fent, G.J.; Foley, J.R.J.; ... ; Plein, S. 2019
